Milan, Italy – December 19th, 2022
Tensive S.r.l., the medical technology company pioneering innovative solutions for reconstructive surgery, announces that it is among the 78 winners of the prestigious EIC Accelerator program (October 2022 cut-off). Tensive was awarded blended finance consisting of a € 2.5 million grant and an additional € 6 million in equity investment.
This award will be crucial to support Tensive in conducting the upcoming clinical trials towards commercialization to bring our revolutionary technology to patients in need.
– Alessandro Tocchio, CSO of Tensive
Tensive was founded in 2012 with the mission to offer breast cancer survivors the option for natural breast reconstruction after lumpectomy, and breast augmentation patients a superior aesthetic outcome through an innovative bio-absorbable implant supporting tissue self-regeneration.
This clinical trial will investigate the safety and performance of REGENERA in 92 female adult subjects aged 40-70 years undergoing reconstructive surgery after excision of a malignant tumor by lumpectomy.
In conjunction with this month’s Breast Reconstruction Awareness (BRA) campaign, IEO (The European Institute of Oncology in Milan) has announced its participation in the study: Istituto Europeo di Oncologia (ieo.it). As part of his summary on developments in the field of breast reconstruction.
Our vision is to improve lumpectomy patients’ quality of life and restore their femininity, avoiding recurrent, painful and expensive surgical operations.
– Valentina Morigi, CFO of Tensive
The loss of a breast can cause a negative psychological impact on breast cancer patients beyond the frightening tumor diagnosis. Among other traumatizing consequences, they experience the loss of femininity and breast sensation.
By using a device designed to be gradually degraded in the body over time and safely replaced by the patient’s soft tissue, breast cancer survivors will preserve a natural breast aspect.
– Margherita Tamplenizza, CQA&RAO of Tensive
Unlike silicone implants and fat grafting, our solution aims to offer a safe, single-surgery option for breast reconstruction with the goal to drastically reduce pain, costs and stress for patients and the healthcare system.
– Irini Gerges, CTO of Tensive
We’d like to thank our team, partners, and quota holders who supported us and worked relentlessly throughout the years towards our ambitious mission.
– Alberto Cantaluppi, President of Tensive
The award of the EIC Accelerator program represents a further validation of Tensive’s vision. We expect that this acknowledgment will enable us to attract additional private investors and venture capitalists to join our company, accelerate market entry, and commercialization.
– Federico Martello, CEO of Tensive
The EIC Accelerator offers start-ups and SMEs grants of up to €2.5 million combined with equity investments through the EIC Fund ranging from €0.5 to €15 million. In addition to financial support, all projects benefit from a range of Business Acceleration Services that provide access to leading expertise, corporates, investors, and ecosystem actors.
Links
EIC announcement: https://eic.ec.europa.eu/news/european-innovation-council-welcomes-78-high-potential-start-ups-and-smes-highly-competitive-2022-12-19_en
For more information about Tensive: https://www.tensive.com
Media Relations: [email protected]